Abrdn Life Sciences Investors (HQL) to Issue Dividend of $0.43 on June 30th

Abrdn Life Sciences Investors (NYSE:HQL) declared a dividend on Tuesday, May 20th, investing.com reports. Investors of record on Friday, May 23rd will be paid a dividend of 0.43 per share on Monday, June 30th. This represents a dividend yield of 13.82%. The ex-dividend date is Thursday, May 22nd.

Abrdn Life Sciences Investors Trading Up 1.5%

Shares of HQL opened at $12.52 on Tuesday. Abrdn Life Sciences Investors has a 12-month low of $10.55 and a 12-month high of $15.90. The business’s fifty day moving average is $12.28 and its 200 day moving average is $13.31.

Insider Buying and Selling at Abrdn Life Sciences Investors

In other Abrdn Life Sciences Investors news, major shareholder Saba Capital Management, L.P. sold 48,623 shares of the firm’s stock in a transaction on Monday, March 31st. The stock was sold at an average price of $12.58, for a total transaction of $611,677.34. Following the transaction, the insider now directly owns 3,188,405 shares in the company, valued at approximately $40,110,134.90. This trade represents a 1.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders have sold 198,861 shares of company stock worth $2,422,653. Corporate insiders own 10.06% of the company’s stock.

Institutional Investors Weigh In On Abrdn Life Sciences Investors

An institutional investor recently raised its position in Abrdn Life Sciences Investors stock. NewEdge Advisors LLC grew its holdings in shares of Abrdn Life Sciences Investors (NYSE:HQL) by 43.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 32,500 shares of the company’s stock after purchasing an additional 9,785 shares during the quarter. NewEdge Advisors LLC owned approximately 0.11% of Abrdn Life Sciences Investors worth $412,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 32.21% of the company’s stock.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.